STOCK TITAN

Rocket Pharmaceuticals, Inc. - $RCKT STOCK NEWS

Welcome to our dedicated page for Rocket Pharmaceuticals news (Ticker: $RCKT), a resource for investors and traders seeking the latest updates and insights on Rocket Pharmaceuticals stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Rocket Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Rocket Pharmaceuticals's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.95%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.47%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
83.39%
Tags
-
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.51%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
conferences
Rocket Pharmaceuticals, Inc.

Nasdaq:RCKT

RCKT Rankings

RCKT Stock Data

2.07B
70.94M
3.66%
102.05%
11.62%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
NEW YORK

About RCKT

rocket pharmaceuticals, ltd is a biotechnology company focused on seeking cures through molecular and gene therapy. we are developing first-in-class treatments for patients with rare and often devastating orphan diseases using a lentiviral-based gene therapy approach. we have developed rewarding partnerships with a number of leading international research institutions as well as with centers of manufacturing and cell processing expertise, while building an internal team to drive the research, development, clinical and regulatory programs. ultimately we aim to launch and globally commercialize innovative gene therapies in disease areas with high unmet need. for more information, please visit www.rocketpharma.com.